Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S179000, C548S180000
Reexamination Certificate
active
07112598
ABSTRACT:
A compound or a salt thereof having the following formulawherein R1is acyl, R2is hydrogen, halogen, unsubstituted alkyl or alkyl substituted by halogen; R3is halogen or alkoxy; R4is cycloalkyl, unsubstituted alkyl or alkyl substituted by cycloalkyl, aryl or hydroxyl or an ester thereof or alkoxy; R5is hydroxyl or an ester thereof, alkoxy or alkoxyalkyl; or R4and R5are bonded with each other to form a pyrrolidine ring substituted by hydroxyl or an ester thereof, alkoxy or alkoxyalkyl; R6is hydroxyl or an ester thereof, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkoxy, mercapto or alkylthio; and A1and A2, are the same or different, and are alkylene, provided that (i) when R4and R5are bonded to each other to form the pyrrolidine ring substituted by hydroxyl or an ester thereof, R2is halogen; (ii) when R4and R5are bonded to each other to form the pyrrolidine ring substituted by alkoxyalkyl, R2is hydrogen; (iii) when R6is hydroxyl or an ester thereof, R4is isopropyl.
REFERENCES:
patent: 4479949 (1984-10-01), Iwao et al.
patent: 4547513 (1985-10-01), Iwao et al.
patent: 6174891 (2001-01-01), Nagase et al.
patent: 58-46079 (1983-03-01), None
patent: 59-67276 (1984-04-01), None
patent: 60-139679 (1985-07-01), None
patent: 61-83175 (1986-04-01), None
patent: 62-221679 (1987-09-01), None
patent: 62-221680 (1987-09-01), None
patent: 8-231399 (1996-09-01), None
patent: WO 98/23290 (1998-06-01), None
Yamamoto, K. et al., “Novel Calcium Antagonists, Synthesis and Structure-Activity Relationship Studies of Benzothiazoline Derivatives”;J. Med. Chem., (1988), 31, 919-930.
Fujita, M. et al., “Synthesis and Calcium Antagonist Activity of (+)—(R)—and (−) (S) -3-Acetyl-2- [5-methoxy-2- [4- [N-methyl-N- (3,4,5-trimethoxyphenethyl) amino] butoxy] -phenyl] benzothiazoline Hydrochloride”,Chem. Pharm. Bull., (1990), 38(4), 936-941.
Way, E.L., “Review of Revues”,Annu. Rev. Pharmacol. Toxicol., (1992), 32, 9-23.
“Experimental Medicine”, 18 (17), 2332-2337 (2000).
Satoh, Masamichi, “Molecular Neuropharmacology of Nociceptive Transmission and Opioid Receptors”,J. Pharm. Soc., 120 (12), 1291-1307, (2000).
“All of Opinoid”, published by Mikusu Co., Ltd., pp. 222-229, (1999).
“All of Opinoid”, published by Mikusu Co., Ltd., pp. 25-36, (1999).
Fujimura Ken-ichi
Honda Takahiro
Kohno Shin-ichi
Niwa Masashi
Osumi Yaeko
Frishauf Holtz Goodman & Chick P.C.
Powers Fiona T.
Santen Pharmaceutical Co. Ltd.
LandOfFree
κ opioid receptor agonist comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with κ opioid receptor agonist comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and κ opioid receptor agonist comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557232